Smoked cannabis for chronic neuropathic pain: a randomized controlled trial

Ware, Mark A.; Wang, Tongtong; Shapiro, Stan; Robinson, Ann; Ducruet, Thierry; Huynh, Thao; Gamsa, Ann; Bennett, Gary J.; Collet, Jean-Paul
October 2010
CMAJ: Canadian Medical Association Journal;10/5/2010, Vol. 182 Issue 14, pE694
Academic Journal
Background: Chronic neuropathic pain affects 1%-2% of the adult population and is often refractory to standard pharmacologic treatment. Patients with chronic pain have reported using smoked cannabis to relieve pain, improve sleep and improve mood. Methods: Adults with post-traumatic or postsurgical neuropathic pain were randomly assigned to receive cannabis at four potencies (0%, 2.5%, 6% and 9.4% tetrahydrocannabinol) over four 14-day periods in a crossover trial. Participants inhaled a single 25-mg dose through a pipe three times daily for the first five days in each cycle, followed by a nine-day washout period. Daily average pain intensity was measured using an 11-point numeric rating scale. We recorded effects on mood, sleep and quality of life, as well as adverse events. Results: We recruited 23 participants (mean age 45.4 [standard deviation 12.3] years, 12 women [52%]), of whom 21 completed the trial. The average daily pain intensity, measured on the 11-point numeric rating scale, was lower on the prespecified primary contrast of 9.4% v. 0% tetrahydrocannabinol (5.4 v. 6.1, respectively; difference = 0.7, 95% confidence interval [CI] 0.02-1.4). Preparations with intermediate potency yielded intermediate but nonsignificant degrees of relief. Participants receiving 9.4% tetrahydrocannabinol reported improved ability to fall asleep (easier, p = 0.001; faster, p < 0.001; more drowsy, p = 0.003) and improved quality of sleep (less wakefulness, p = 0.01) relative to 0% tetrahydrocannabinol. We found no differences in mood or quality of life. The most common drug-related adverse events during the period when participants received 9.4% tetrahydrocannabinol were headache, dry eyes, burning sensation in areas of neuropathic pain, dizziness, numbness and cough. Conclusion: A single inhalation of 25 mg of 9.4% tetrahydrocannabinol herbal cannabis three times daily for five days reduced the intensity of pain, improved sleep and was well tolerated. Further long-term safety and efficacy studies are indicated. (International Standard Randomised Controlled Trial Register no. ISRCTN68314063)


Related Articles

  • More evidence cannabis can help in neuropathic pain. McQuay, Henry J. // CMAJ: Canadian Medical Association Journal;10/5/2010, Vol. 182 Issue 14, p1494 

    The article presents a study on the efficacy of cannabis in prevention and treatment of neuropathic pain. It highlights the most common way that cannabis is used which is through smoking. As researchers confirmed its analgesic activity of cannabis, a randomized controlled trial among 21...

  • Efficacy, Safety, and Tolerability of Pregabalin for Diabetic Peripheral Neuropathic Pain. Kuritzky, Louis // Clinical Cardiology Alert;Sep2008 Clinical Briefs in Primary, Vol. 13 Issue 9, p18 

    This article discusses research being done on the effectiveness, safety and tolerability of pregabalin for diabetic peripheral neuropathic pain (DPNP) management. It references a study by R. Freeman et al, published in a 2008 issue of "Diabetes Care." The researchers based the study on data from...

  • Efficacy, Safety, and Tolerability of Pregabalin Treatment for Painful Diabetic Peripheral Neuropathy. Freeman, Roy; Durso-Decruz, Edith; Emir, Birol // Diabetes Care;Jul2008, Vol. 31 Issue 7, p1448 

    OBJECTIVE -- To evaluate the efficacy, safety, and tolerability of pregabalin across the effective dosing range, to determine differences in the efficacy of three times daily (TID) versus twice daily (BID) dosage schedules, and to use time-to-event analysis to determine the time to onset of a...

  • How Should the Impact of Different Presentations of Treatment Effects on Patient Choice Be Evaluated? A Pilot Randomized Trial. Carling, Cheryl; Kristoffersen, Doris Tove; Herrin, Jeph; Treweek, Shaun; Oxman, Andrew D.; Sch√ľnemann, Holger; Akl, Elie A.; Montori, Victor // PLoS Clinical Trials;Nov2008, Vol. 5 Issue 11, p1 

    Background: Different presentations of treatment effects can affect decisions. However, previous studies have not evaluated which presentations best help people make decisions that are consistent with their own values. We undertook a pilot study to compare different methods for doing this....

  • ERRATUM.  // Journal of Pain Research;2013, Vol. 6, p641 

    A correction to an article published in a previous issue of the journal is presented that used the word "phytosome" and "Meriva" instead of "Phytosome" and "Meriva."

  • Femoral neuropathy caused by hyperlordotic positioning. Albrecht, Peter; Grosse, Joachim; Neukaeter, Winfried // Journal of Anesthesia;Oct2014, Vol. 28 Issue 5, p800 

    A letter to the editor is presented reporting a case of femoral neuropathy caused by hyperlordotic positioning in a 32-year-old man.

  • Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection. Hesselink, J. M. Keppel // International Medical Case Reports Journal;2013, Vol. 6, p49 

    Chronic idiopathic axonal polyneuropathy is a frequent diagnosis in patients suffering from idiopathic polyneuropathy and neuropathic pain. No guidelines exist on how to treat these patients. To date, there are no results available from randomized clinical trials, and mostly classical...

  • Pooled Analysis of 7 Randomized, Controlled Trials of Pregabalin as Treatment of Painful Diabetic Peripheral Neuropathy (DPN): Efficacy, Safety, Tolerability. Freeman, R.; Rosenstock, J.; Emir, B.; Durso-Decruz, E. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA577 

    To more fully describe pregabalin as treatment of painful DPN across its effective dosing range (150-600 mg/d, BID or TID), we pooled data from 7 randomized controlled trials of 5-13 weeks' duration. 1510 patients comprised the pooled ITT population: 557 received placebo (PBO), and 953 received...

  • Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Hirayama, Yasuo; Ishitani, Kunihiko; Sato, Yasushi; Iyama, Satoshi; Takada, Kohichi; Murase, Kazuyuki; Kuroda, Hiroyuki; Nagamachi, Yasuhiro; Konuma, Yuichi; Fujimi, Akihito; Sagawa, Tamotsu; Ono, Kaoru; Horiguchi, Hiroto; Terui, Takeshi; Koike, Kazuhiko; Kusakabe, Toshiro; Sato, Tsutomu; Takimoto, Rishu; Kobune, Masayoshi; Kato, Junji // International Journal of Clinical Oncology;Oct2015, Vol. 20 Issue 5, p866 

    Background: Chemotherapy-induced peripheral neuropathy (CIPN) is difficult to manage. A phase III trial conducted in the United States demonstrated that duloxetine was effective for CIPN caused by taxane and platinum-based chemotherapy. No randomized trial of duloxetine for CIPN has been...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics